Pneumonitis Prevention Protocol Using Pentoxifylline and α-tocopherol In Stage III Non-Small Cell Lung Cancer Patients Undergoing Chemoradiation
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Currently, the standard of care treatment for newly diagnosed, inoperable stage III non-small cell lung cancer is radiotherapy (RT) with concurrent chemotherapy, followed by immune checkpoint inhibitors (ICI). RT is a highly effect local treatment. However, high doses of radiation used in curative settings can cause adverse side effects. The most common RT side effect in lung cancer is Radiation Induced Lung Injury (RILI), which can manifest as pneumonitis and/or pulmonary fibrosis. Lung injury can negatively impact patients' well-being and quality of life, and may lead to increased mortality. Risk of lung injury is particularly increased when patients are treated with a combination of treatments (i.e., RT, chemotherapy, and ICI). The drug Pentoxifylline (in combination with α-Tocopherol (Vitamin E)) has been shown to prevent/alter the progression of lung injury and there is a growing body of evidence to support the safety and efficacy of phosphodiesterase inhibitors in cancer treatment. The proposed study aims to determine if the addition of Pentoxifylline, given in combination with α-Tocopherol (Vitamin E), to standard of care treatment will reduce side effects related to lung injury and improve quality of life in this study population.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 18 lat
- •Potwierdzony rozpoznaniem rak płuca w stadium III, niekwalifikujący się do operacji
- •Planowana chemioterapia i radioterapia łącznie z immunoterapią
- •Sprawna funkcja wątroby (bez zapalenia wątroby stadium C)
- •Sprawna funkcja nerek (oczyszczanie kreatyniny > 50 mL/min)
✗ Disqualifies
- •Uczestnictwo w innym badaniu w ciągu ostatnich 6 miesięcy
- •Wcześniejsza radioterapia w obrębie planowanego leczenia
- •Ciąża
- •Oczekiwana długość życia poniżej 12 miesięcy
- •Alergia na pentoksyfilinę, witaminę E lub kofeínę
- •Niedawny zawał serca (w ciągu 3 miesięcy) lub zaburzenia rytmu serca
- •Krwawienie lub wysokie ryzyko krwawienia
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- August 6, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
University Health Network - Princess Margaret Cancer Centre
Toronto, Canada
Trial contact
Philip Wong MD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/7/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.